Compare

Aytu Biopharma, Inc vs Nektar Therapeutics vs Nuvation Bio Inc. vs Ocular Therapeutix, Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAytu Biopharma, Inc
AYTU
Nektar Therapeutics
NKTR
Nuvation Bio Inc.
NUVB
Ocular Therapeutix, Inc
OCUL
Year ended2026-06-302025-12-312025-12-312025-12-31
Revenue$57.57M$55.23M$62.90M$51.95M
Revenue growth (YoY)-13.3%-43.9%+699.0%-18.5%
Gross margin64.0%n/an/a87.3% (computed)
Operating margin-14.4%-253.7%-338.7%-519.8%
Net margin-24.8%-297.1%-325.3%-511.9%
Net income-$14.25M-$164.08M-$204.63M-$265.94M
EPS (Diluted)n/a-$9.73-$0.60-$1.42
Operating cash flow$3.28M-$208.51M-$173.43M-$204.88M
Free cash flow$3.25M-$208.68Mn/a-$216.89M
Cash & equivalents$26.31M$15.12M$164.09M$737.06M
Total assets$105.01M$280.41M$594.82M$808.06M
Total liabilitiesn/a$190.57M$289.11M$153.75M
Shareholders' equity$35.27M$89.83M$305.72M$654.31M
Return on year-end equity-40.4%-182.6%-66.9%-40.6%
Shares outstanding10.73M20.38M337.84M215.93M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAytu Biopharma, IncNektar TherapeuticsNuvation Bio Inc.Ocular Therapeutix, Inc
Latest$57.57M
Ended 2026-06-30
$55.23M
Ended 2025-12-31
$62.90M
Ended 2025-12-31
$51.95M
Ended 2025-12-31
1 year earlier$66.38M
Ended 2025-06-30
$98.43M
Ended 2024-12-31
$7.87M
Ended 2024-12-31
$63.72M
Ended 2024-12-31
2 years earlier$65.18M
Ended 2024-06-30
$90.12M
Ended 2023-12-31
$0
Ended 2023-12-31
$58.44M
Ended 2023-12-31
3 years earlier$107.40M
Ended 2023-06-30
$92.06M
Ended 2022-12-31
n/a$51.49M
Ended 2022-12-31
4 years earlier$96.67M
Ended 2022-06-30
$101.91M
Ended 2021-12-31
n/a$43.52M
Ended 2021-12-31